Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

1.1.3 Immunosuppressants

 

Mirikizumab (Omvoh®)

This High-Cost Drug has been approved for the following indications: - for treating moderately to severely active ulcerative colitis in adults as per NICE TA925.   
For more information and NICE Guidance Click Here Mirikizumab for treating moderately to severely active ulcerative colitis NICE TA925
ICB commissioned - approval via Blueteq


Ozanimod

This High-Cost Drug has been approved for the following indications: - Ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults only if: when conventional or biological treatments cannot be tolerated or are not working well enough, and infliximab is not suitable, and the company provides it according to the commercial arrangement.   
For more information and NICE Guidance Click Here Ozanimod for treating moderately to severely active ulcerative colitis NICE TA828
ICB commissioned - approval via Blueteq
Risankizumab - SKYRIZI® This High-Cost Drug has been approved for the following indications: - Treatment of previously treated moderately to severely active Crohn’s disease 
For more information and NICE Guidance Click Here

Risankizumab for previously treated moderately to severely active Crohn's disease NICE Guidance TA888
ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Adolescents 16 - 17)
    Upadacitinib This High-Cost Drug has been approved for the following indications: - Treatment of moderately to severely active ulcerative colitis in adults: when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments as per NICE Guidance
For more information and NICE Guidance Click Here Upadacitinib for treating moderately to severely active ulcerative colitis NICE Guidance TA856
Upadacitinib This High-Cost Drug has been approved for the following indications: - Treatment of previously treated moderately to severely active Crohn’s disease
For more information and NICE Guidance Click Here Upadacitinib for previously treated moderately to severely active Crohn’s disease NICE Guidance TA905 

 

 

 

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •